Literature DB >> 12172913

Lewy bodies in progressive supranuclear palsy.

Hideo Mori1, Masaya Oda, Takashi Komori, Nobutaka Arai, Masashi Takanashi, Toshio Mizutani, Shunnichi Hirai, Yosikuni Mizuno.   

Abstract

Lewy bodies (LBs), whose major component is alpha-synuclein, are a pathological hallmark of Parkinson's disease (PD) but have rarely been reported in progressive supranuclear palsy (PSP). Whether LBs in PSP represent the aging process or the coexistence of PD remains unclear. We found LBs in 5 of 16 patients with PSP. In 4 patients LBs were distributed widely throughout the brain stem and cerebrum in a pattern similar to that in PD. In the remaining patient one LB was found in the pontine reticular formation. Semiquantitative analysis showed that neuronal loss in the locus coeruleus and the dorsal vagal nucleus was more severe in patients with LBs than in patients without LBs. Double-labeling immunohistochemical studies showed co-localization of alpha-synuclein and tau in some neurons. Our study suggests that patients who have PSP with LBs constitute a subset of patients with PSP in whom Lewy body disease is also present.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12172913     DOI: 10.1007/s00401-002-0555-3

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  17 in total

Review 1.  Co-existence of Parkinson's disease and progressive supranuclear palsy: case report and a review of the literature.

Authors:  Kumar Abhinav; Laura Marsh; Barbara Crain; Stephen G Reich; Kevin Biglan
Journal:  Neurol Sci       Date:  2010-08-25       Impact factor: 3.307

2.  Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia.

Authors:  Jonathan Wills; Jessica Jones; Thomas Haggerty; Valeriy Duka; Jeffrey N Joyce; Anita Sidhu
Journal:  Exp Neurol       Date:  2010-06-28       Impact factor: 5.330

3.  Diffuse Lewy Body Disease and Alzheimer Disease: Neuropathologic Phenotype Associated With the PSEN1 p.A396T Mutation.

Authors:  Dibson D Gondim; Adrian Oblak; Jill R Murrell; Rose Richardson; Francine Epperson; Owen A Ross; Bernardino Ghetti
Journal:  J Neuropathol Exp Neurol       Date:  2019-07-01       Impact factor: 3.685

4.  The neurotoxin, MPP+, induces hyperphosphorylation of Tau, in the presence of alpha-Synuclein, in SH-SY5Y neuroblastoma cells.

Authors:  Tetyana Duka; Anita Sidhu
Journal:  Neurotox Res       Date:  2006-08       Impact factor: 3.911

5.  Progressive supranuclear palsy: progression and survival.

Authors:  Julieta E Arena; Stephen D Weigand; Jennifer L Whitwell; Anhar Hassan; Scott D Eggers; Günter U Höglinger; Irene Litvan; Keith A Josephs
Journal:  J Neurol       Date:  2015-12-24       Impact factor: 4.849

6.  Cortical Alzheimer type pathology does not influence tau pathology in progressive supranuclear palsy.

Authors:  Kenichi Oshima; Dennis W Dickson
Journal:  Int J Clin Exp Pathol       Date:  2008-12-20

7.  Clinical Features of Patients with Concomitant Parkinson's Disease and Progressive Supranuclear Palsy Pathology.

Authors:  Heather B Rigby; Brittany N Dugger; Joseph G Hentz; Charles H Adler; Thomas G Beach; Holly A Shill; Erika Driver-Dunckley; Marwan N Sabbagh; Lucia I Sue; John N Caviness
Journal:  Mov Disord Clin Pract       Date:  2014-10-29

8.  Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis?

Authors:  B Mollenhauer; M Bibl; H Esselmann; P Steinacker; C Trenkwalder; J Wiltfang; M Otto
Journal:  J Neural Transm (Vienna)       Date:  2007-02-22       Impact factor: 3.850

9.  The Relationship between Parkin and Protein Aggregation in Neurodegenerative Diseases.

Authors:  Preeti J Khandelwal; Charbel E-H Moussa
Journal:  Front Psychiatry       Date:  2010-06-03       Impact factor: 4.157

10.  Ultrasensitive Detection of Aggregated α-Synuclein in Glial Cells, Human Cerebrospinal Fluid, and Brain Tissue Using the RT-QuIC Assay: New High-Throughput Neuroimmune Biomarker Assay for Parkinsonian Disorders.

Authors:  Sireesha Manne; Naveen Kondru; Monica Hepker; Huajun Jin; Vellareddy Anantharam; Mechelle Lewis; Xuemei Huang; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  J Neuroimmune Pharmacol       Date:  2019-01-31       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.